Please login to the form below

Not currently logged in
Email:
Password:

AiCuris

This page shows the latest AiCuris news and features for those working in and with pharma, biotech and healthcare.

EC grants MSD’s Prevymis orphan product designation

EC grants MSD’s Prevymis orphan product designation

The treatment - which MSD acquired from German biotech AiCuris - has already been approved for use in the same disease indication for the US last year.

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    $142m upfront payment representing approximately 25 per cent of the consideration is certainly attractive for AiCuris and probably reflects the fact that this drug is for an orphan indication. . ... 587. AiCuris / Merck &Co. Licence. Letermovir (phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • TiGenix appoints Dr Marie Paule Richard TiGenix appoints Dr Marie Paule Richard

    She takes on role as chief medical officer and brings experience from Aicuris and Crucell. ... An immunologist with over 25 years of experience in the global biopharmaceutical industry, Richard has previously served as chief medical officer at Aicuris in

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Measures for measures
Why pharma’s marketing metrics must close the loop...
Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...

Infographics